These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19550334)

  • 1. Second-line therapy in bladder cancer.
    Bachner M; De Santis M
    Curr Opin Urol; 2009 Sep; 19(5):533-9. PubMed ID: 19550334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder.
    De Santis M; Bachner M
    Curr Opin Urol; 2007 Sep; 17(5):363-8. PubMed ID: 17762632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vinflunine in the treatment of advanced bladder cancer.
    Mamtani R; Vaughn DJ
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):13-20. PubMed ID: 21166506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review.
    Gerullis H; Ecke T; Eimer C; Wishahi M; Otto T
    Anticancer Drugs; 2011 Jan; 22(1):9-17. PubMed ID: 20948429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting.
    Gallagher DJ; Milowsky MI; Bajorin DF
    Cancer; 2008 Sep; 113(6):1284-93. PubMed ID: 18629841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.
    Ortmann CA; Mazhar D
    Future Oncol; 2013 Nov; 9(11):1637-51. PubMed ID: 24156324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance.
    Gerullis H; Ecke TH; Janusch B; Arndt C; Heidari M; Oniani J; Otto T
    Anticancer Drugs; 2011 Oct; 22(9):940-3. PubMed ID: 21642839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinflunine.
    Prescrire Int; 2011 Jan; 20(112):11-3. PubMed ID: 21462785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant activity of single agent vinorelbine against small-cell cancer of the bladder as second line chemotherapy: a case series and review of the literature.
    June RR; Dougherty DW; Reese CT; Harpster LE; Hoffman SL; Drabick JJ
    Urol Oncol; 2012; 30(2):192-5. PubMed ID: 20363163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of locally advanced bladder cancer: early vs deferred chemotherapy.
    Syed S; Weiss GR
    World J Urol; 2002 Aug; 20(3):175-82. PubMed ID: 12196901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.
    Bellmunt J; Delgado FM; George C
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S34-43. PubMed ID: 18538178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium.
    Sonpavde G; Sternberg CN; Rosenberg JE; Hahn NM; Galsky MD; Vogelzang NJ
    Lancet Oncol; 2010 Sep; 11(9):861-70. PubMed ID: 20537950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bladder preservation: optimizing radiotherapy and integrated treatment strategies.
    Mak RH; Zietman AL; Heney NM; Kaufman DS; Shipley WU
    BJU Int; 2008 Nov; 102(9 Pt B):1345-53. PubMed ID: 19035903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-adapted use of intravesical chemotherapy.
    Lerner SP; Au JL
    BJU Int; 2008 Nov; 102(9 Pt B):1247-53. PubMed ID: 19035889
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of disseminated disease in the patient with bladder cancer.
    Perry JJ; Muss HB
    Urol Clin North Am; 1994 Nov; 21(4):661-72. PubMed ID: 7974898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolving role of chemotherapy in advanced urothelial cancer.
    Calabrò F; Sternberg CN
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):180-6. PubMed ID: 18685360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted agents in second-line bladder cancer therapy.
    Gerullis H; Otto T; Ecke TH
    Anticancer Drugs; 2012 Nov; 23(10):1003-15. PubMed ID: 22914698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.
    Bellmunt J; Fougeray R; Rosenberg JE; von der Maase H; Schutz FA; Salhi Y; Culine S; Choueiri TK
    Ann Oncol; 2013 Jun; 24(6):1466-72. PubMed ID: 23419284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness, toxicity, and economic evaluation of vinflunine for the treatment of patients with transitional cell carcinoma in the Spanish outpatient setting.
    Guglieri-López B; Pérez-Pitarch A; Porta-Oltra B; Ferriols-Lisart F; Climente-Martí M; Alós-Almiñana M
    Anticancer Drugs; 2015 Sep; 26(8):860-5. PubMed ID: 25919319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.